Skip to main content

Oncolytic Virus Therapies Market is projected to grow at a whopping CAGR of 26.28% over the period 2020-2030

 The global oncolytic virus therapies market is undergoing a significant flux with regard to the advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of virus therapeutics, there is an immense potential for these emerging sub-markets to continue fueling the overall oncolytic virus therapies market. This chapter reviews the significant drivers and restraints that are considerably impacting the dynamicity of the global oncolytic virus therapies market.

Due to the ever-rising incidence of cancers, the need for better products and services is becoming more evident. Several key players are aligning their technologies as per the market requirements to provide technologically advanced products and services by adopting inorganic strategies such as agreements, partnerships, and collaborations.

The global oncolytic virus therapies market is projected to grow at a whopping CAGR of 26.28% over the period 2020-2030 and reach a market value of $962 million by 2030. 



The challenges associated with the global oncolytic virus therapies market are High cost of therapy and lack of therapy-specific-assays may cause hindrance in the adoption of oncolytic virus therapies globally. In 2020, the North American region held the largest share in the global market for oncolytic virus therapies owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region.


Market Segmentation

•    Commercialized Therapies: Imlygic, Oncorine, and RIGVIR

•    Pipeline Therapies: Phase I, Phase II, Phase III

•    Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)

•    Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)


Regional Segmentation

•    North America: U.S.

•    Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)

•    Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)


Growth Drivers

•    Increasing Incidence of Cancer

•    Rising Number of Clinical Trials

•    Increasing Research Funding from National Cancer Institute

•    Increasing Adoption of Inorganic Growth Strategies in the Market


Market Restraints

•    High Cost of Therapy

•    Lack of Therapy-Specific Assays


Market Opportunities

•    Opportunities in the Emerging Economies

•    Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies


Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.


Request a Sample- https://bisresearch.com/requestsample?id=1099&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Pharmacogenomics Services Market Dynamics, Competitive Landscape & Forecast to 2031

  BIS healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global  pharmacogenomics services market  is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug
Post a Comment
Read more

PP Compound Market for Automotive Industry Open Up New Revenue Opportunities

  The global PP compound market for automotive industry is expected to reach $17,324.8 million by 2031, with a CAGR of 5.6% during the forecast period 2021-2031. The growth in the market is expected to be driven mainly by the need to reduce the weight of vehicles and demand for cheaper products that can be used in automotive parts. Impact of COVID-19 on the Global Polypropylene (PP) Compound Market for Automotive Industry Due to the COVID–19 pandemic, the PP compound market was severely impacted like many other industries. Automotive production in 2020 saw a decline of almost 16% due to the impact of COVID-19. In order to control the spread of the virus, the majority of the countries around the globe imposed stay-at-home orders, which led to the shutting of many manufacturing plants. As the production of vehicles declined, the demand for PP compounds suffered negatively in the year 2020. Market Segmentation Global Polypropylene (PP) Compound Market for Automotive Industry by Applicatio
Post a Comment
Read more